Text Size

MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis (MELT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Ferring Arzneimittel GmbH
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01368913
First received: June 7, 2011
Last updated: April 24, 2013
Last verified: April 2013
History of Changes

June 7, 2011
April 24, 2013
June 2011
March 2013   (final data collection date for primary outcome measure)
Assessment of patient and parent satisfaction [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01368913 on ClinicalTrials.gov Archive Site
  • Number of wet nights [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of drinking volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of urine volume [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Assessment of patient compliance [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction

Desmopressin in treatment of nocturnal enuresis (bedwetting).
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with primary nocturnal enuresis
Nocturnal Enuresis
Not Provided
  • Patients treated with orally disintegrating tablet
  • Patients treated with tablets
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
138
May 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency
  • The patients and their parents have been informed about the study and have given their written consent for participation.

Exclusion Criteria:

  • The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated
Both
5 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01368913
000018
No
Ferring Pharmaceuticals
Ferring Pharmaceuticals
Ferring Arzneimittel GmbH
Study Director: Clinical Development Support Ferring Pharmaceuticals
Ferring Pharmaceuticals
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP